Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001310

Drug Information
NameMefloquine
SynonymsAC1L1HAJ; NCGC00161831-02; WR-142,490; Spectrum4_001066; SPBio_001591; Mefloquina [INN-Spanish]; SPBio_002111; Racemic mefloquine; mefloquine; DivK1c_000790; Prestwick3_000126; Prestwick1_000126; CHEMBL411329; SPECTRUM1503070; Mefloquinum; DB00358; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; WR-177,602; (+)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11S, 2'S)-; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; AC1L9UO6; nchembio.215-comp3; Ro-21-5998-001; NSC157387; 51742-87-1; BRD-A89585551-003-03-4; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Prestwick0_000126; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; CID40692; RTI1172-1-1; BIDD:PXR0166; CHEBI:151162; (+)-(11R,2'S)-erythro-Mefloquine; (+/-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; BPBio1_000190; NCGC00016864-01; C17H16F6N2O; 68682-27-9; AB00052310; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-; Ro 21-5998; C07633; AC1MHD7O; (+)-Threo-Mefloquine; (-)-Threo-Mefloquine; RTI1173-1-1; HSDB 6853; NINDS_000790; HMS502H12; MolPort-003-981-155; RTI1174-1-1; CHEBI:403542; CHEMBL416956; NCGC00161831-01; MQ; Lariam (Hydrochloride); AC1MHD7J; 53230-10-7; (+)-Mefloquine; AC1Q4K1I; HMS1922C09; KBioGR_001392; Mefloquine (USAN/INN); 4-Quinolinemethanol, alpha-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaR)-; RTI1169-1-1; 4-Quinolinemethanol, .alpha.-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.S)-; CID456309; Mefloquinone; RTI1189-1-1; 4-Quinolinemethanol, .alpha.-(2S)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (.alpha.R)-; (+)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 49752-90-1; 4-Quinolinemethanol, alpha-(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (alphaS)-rel-; BIDD:GT0596; Mephloquine; NCGC00094994-02; 51744-84-4; LS-187797; CID3000506; nchembio.87-comp20; Spectrum5_001122; RO 13-7225; RO 13-7224; CID3000516; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; IDI1_000790; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; Lariam; Mefloquinum [INN-Latin]; NCGC00094994-01; KBio2_006928; EINECS 256-468-3; Mefloquin; Spectrum2_001516; 51688-68-7; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; KBio1_000790; RTI1188-1-1; 51744-85-5; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; CAS-51773-92-3; (-)-threo-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (11R, 2'R)-; 4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(.+/-.)-; (+/-)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+/-)-; SPB-80406; AR-1G4597; WR 142490; WR-142490; CHEMBL411685; KBio3_002046; KBioSS_001792; AC1L249S; NCGC00094994-04; Spectrum3_000953; alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; CHEMBL411686; D04895; alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; KBio2_001792; (-)-(11S,2'R)-erythro-Mefloquine; Mefloquine [USAN:INN:BAN]; (-)-Mefloquine; UNII-TML814419R; Prestwick2_000126; Ro 21-5998 (Hydrochloride); Mefloquina; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)-; 4-quinolinemethanol, a-2-piperidinyl-2,8-bis(trifluoromethyl)-; KBio2_004360; CID4046; LS-142023; NCGC00094994-03; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-; BSPBio_000172; Spectrum_001312; Ro 215998
Trade NameLariam; Mefaquin
CompanyHoffmann-La Roche pharmaceutical company
IndicationMalaria
[ICD9: 084   ICD10: B50-B54]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)
8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15
+/m1/s1
InChIKeyXEEQGYMUWCZPDN-DOMZBBRYSA-N
Canonical SMILESC1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O    
Isomeric SMILESC1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
Therapeutic ClassAntimalarials
CAS NumberCAS 53230-10-7
FormulaC17H16F6N2O
PubChem Compound IDCID 40692.
PubChem Substance IDSID 181524.
SuperDrug ATC IDP01BC02
SuperDrug CAS ID053230107;
TargetFood vacuolesBinder[2]
Ref 1The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. To Reference
Ref 2An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543